Duncan

We're doing it slightly differently again this week.

And Helen, you've started to think a bit more about the ethics in guidelines.

Well, that's a very important point from Julian at the end there.

I suppose on that, just picking up on that point about passing them back to science, that's implied that there's some monolithic science answer to these things, as opposed to being very dependent on the questions that you're actually asking and the place from which you're standing when you ask them.

Carl?

And I suppose the bit that struck me was when he was talking about the people who are disabled or in other ways marginalised being particularly worried about this.

And it occurred to me, how involved are they as a particular group in any guideline development?

Yeah, absolutely.

Before we move on, here's a quick message from our editor.

Right, back to the show.

Have you seen anything interesting, new research that's popped up that's caught your eye this week that we could have a very quick little update on?

Well, sometimes, you know, this is not just about clinical stuff.

These things are important when it comes to talking about transmission and some of the big questions that we've been answering.

So there we go.

We've talked a little bit about guidelines and had a quick update.

But as always in this podcast, we seem to be echoing back to the fact that the problems in EBM are just being

amplified and exposed by what's happening in coronavirus.

And one of those problems that we've talked about before is waste in research.

Now, Helen, you went and talked to someone who's an expert in this about it.

Yeah, those reporting statements, all the journals will want them anyways.